Imperial College London
Portrait Picture

ProfessorGrahamCooke

Faculty of Medicine, Department of Infectious Disease

Vice Dean (Research); Professor of Infectious Diseases
 
 
 
//

Contact

 

g.cooke

 
 
//

Location

 

Infectious Diseases SectionMedical SchoolSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Drake:2021:10.1016/S2665-9913(21)00104-1,
author = {Drake, TM and Fairfield, CJ and Pius, R and Knight, SR and Norman, L and Girvan, M and Hardwick, HE and Docherty, AB and Thwaites, RS and Openshaw, PJM and Baillie, JK and Harrison, EM and Semple, MG and ISARIC4C, Investigators},
doi = {10.1016/S2665-9913(21)00104-1},
journal = {The Lancet Rheumatology},
pages = {e498--e506},
title = {Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study},
url = {http://dx.doi.org/10.1016/S2665-9913(21)00104-1},
volume = {3},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background: Early in the pandemic it was suggested that pre-existing use of non-steroidal anti-inflammatory drugs (NSAIDs) could lead to increased disease severity in patients with COVID-19. NSAIDs are an important analgesic, particularly in those with rheumatological disease, and are widely available to the general public without prescription. Evidence from community studies, administrative data, and small studies of hospitalised patients suggest NSAIDs are not associated with poorer COVID-19 outcomes. We aimed to characterise the safety of NSAIDs and identify whether pre-existing NSAID use was associated with increased severity of COVID-19 disease. Methods: This prospective, multicentre cohort study included patients of any age admitted to hospital with a confirmed or highly suspected SARS-CoV-2 infection leading to COVID-19 between Jan 17 and Aug 10, 2020. The primary outcome was in-hospital mortality, and secondary outcomes were disease severity at presentation, admission to critical care, receipt of invasive ventilation, receipt of non-invasive ventilation, use of supplementary oxygen, and acute kidney injury. NSAID use was required to be within the 2 weeks before hospital admission. We used logistic regression to estimate the effects of NSAIDs and adjust for confounding variables. We used propensity score matching to further estimate effects of NSAIDS while accounting for covariate differences in populations. Results: Between Jan 17 and Aug 10, 2020, we enrolled 78674 patients across 255 health-care facilities in England, Scotland, and Wales. 72179 patients had death outcomes available for matching; 40406 (56·2%) of 71915 were men, 31509 (43·8%) were women. In this cohort, 4211 (5·8%) patients were recorded as taking systemic NSAIDs before admission to hospital. Following propensity score matching, balanced groups of NSAIDs users and NSAIDs non-users were obtained (4205 patients in each group). At hospital admission, we observed no si
AU  - Drake,TM
AU  - Fairfield,CJ
AU  - Pius,R
AU  - Knight,SR
AU  - Norman,L
AU  - Girvan,M
AU  - Hardwick,HE
AU  - Docherty,AB
AU  - Thwaites,RS
AU  - Openshaw,PJM
AU  - Baillie,JK
AU  - Harrison,EM
AU  - Semple,MG
AU  - ISARIC4C,Investigators
DO  - 10.1016/S2665-9913(21)00104-1
EP  - 506
PY  - 2021///
SN  - 2665-9913
SP  - 498
TI  - Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study
T2  - The Lancet Rheumatology
UR  - http://dx.doi.org/10.1016/S2665-9913(21)00104-1
UR  - https://www.ncbi.nlm.nih.gov/pubmed/33997800
UR  - https://www.sciencedirect.com/science/article/pii/S2665991321001041?via%3Dihub
UR  - http://hdl.handle.net/10044/1/89216
VL  - 3
ER  -
Download